Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-126 in mild to moderate Alzheimer's disease
NCT01527916Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of nelonicline in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Feb 2012; status: completed.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01527916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527916.